Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Disease × Vincristine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 57 Lymphoma, Large B-Cell, Diffuse 40 Precursor Cell Lymphoblastic Leukemia-Lymphoma 39 Lymphoma, Follicular 33 Leukemia 30 Lymphoma, Non-Hodgkin 28 Burkitt Lymphoma 19 Hodgkin Disease 18 Neuroblastoma 13 Lymphoma, Large-Cell, Immunoblastic 12 Central Nervous System Neoplasms 12 Sarcoma 10 Multiple Myeloma 10 Lymphoma, Mantle-Cell 10 Rhabdomyosarcoma 9 Wilms Tumor 7 Lymphoma, T-Cell, Peripheral 7 Lymphoma, Large-Cell, Anaplastic 7 Lymphoma, B-Cell, Marginal Zone 7 Oligodendroglioma 6 Neuroectodermal Tumors, Primitive, Peripheral 5 Neoplasms, Plasma Cell 5 Neoplasms 5 Malignant mesenchymal tumor 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Brain Neoplasms 5 Astrocytoma 5 Retinoblastoma 4 Recurrence 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4

Interventions

Magnetic Resonance Spectroscopy 3 Prednisone 2 Positron-Emission Tomography 2 Lenalidomide 2 Injections 2 Dexamethasone 2 Cyclophosphamide 2 technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1 obinutuzumab 1 lortalamine 1 fluciclovine F-18 1 Vindesine 1 Vincristine 1 Transplantation, Autologous 1 Thalidomide 1 Rituximab 1 Mitomycin 1 Melphalan 1 Doxorubicin 1 Diagnosis 1 Bleomycin 1 3-Iodobenzylguanidine 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01659099 2018-03-07

GAINED

The Lymphoma Academic Research Organisation

Phase 3 Terminated

Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡